$8.86−0.07 (−0.73%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
Telix Pharmaceuticals (TLX) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
6 figures withheld by our checks. Each blank figure names its reason.
Business engineGrowing fast: revenue compounds ~96.1%/yr (FY22→FY25), net margin −1.9%. Worth your attention in FY25: Capex step-up ($43.8M). Visible in the receipts below.
The four lines that matter · FY22–FY25
Revenue ($M)▲55.4%
821.4
FY22→FY25CAGR +96.1%/yr
Net income ($M)—
−15.5
FY22→FY25CAGR —
Free cash flow ($M)—
−61.1
no value for 1 of 4 yearsCAGR —
Diluted EPS—
—
no FY25 valueCAGR —
What the receipts whisper · what a headline number hides
Capex step-up
$43.8M
▲97% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY22–FY25
Where every revenue dollar goes · FY25 ($M)
-2¢ of every revenue dollar becomes profit. The biggest cost lever is COGS.
Margin trend · direction beats level Operating Net
Net margin -1.9% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.
The receipt · income statement · FY22–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | FY25 † | FY25 | FY24 | FY23 | FY22 | YoY | CAGR 22→25 |
|---|---|---|---|---|---|---|---|
| Revenue & profitability | |||||||
Revenue | 821,355.0 | 821,355.0 | 528,616.0 | 309,822.0 | 108,945.3 | ▲55.4% | +96.1% |
Cost of revenue | 462,817.0 | 462,817.0 | 221,500.0 | 138,781.0 | 44,348.2 | ▲108.9% | +118.5% |
Gross profit | — | —A | 336,163.0 | 209,533.0 | 64,597.1 | — | — |
Research & development | 171,249.0 | 171,249.0 | 127,930.0 | 85,315.0 | 54,907.5 | ▲33.9% | +46.1% |
Selling, general & admin | 95,789.0 | 95,789.0 | 85,318.0 | 49,668.0 | 32,089.7 | ▲12.3% | +44.0% |
Total operating expenses | 363,804.0 | 363,804.0 | 269,201.0 | 168,447.0 | 111,708.2 | ▲35.1% | +48.2% |
Operating incomefeeds ROC rank | −5,266.0 | −5,266.0 | 37,915.0 | 2,594.0 | −62,558.4 | — | — |
Other income, net | −1,242.0 | −1,242.0 | −3,287.0 | −612.0 | −4,553.9 | — | — |
Pretax income | −6,508.0 | −6,508.0 | 34,628.0 | 1,982.0 | −67,112.3 | — | — |
Income tax | 1,859.0 | 1,859.0 | 4,230.0 | −1,614.0 | 3,713.5 | ▼56.1% | −20.6% |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −15,492.0 | −15,492.0 | 64,083.0 | 7,804.0 | −70,825.8 | — | — |
| Per share | |||||||
Diluted EPSbuyback-sensitive | — | — | — | — | −22.80 | — | — |
Diluted shares (mn) | 338.78 | 338.78 | 334.72 | — | — | ▲1.2% | — |
| Margins | |||||||
Gross margin | — | —B | —B | —B | —B | — | — |
Operating margin | −0.6% | −0.6% | 7.2% | 0.8% | −57.4% | ▼7.8pp | +56.8pp |
Net margin36th pct in Healthcare | −1.9% | −1.9% | 12.1% | 2.5% | −65.0% | ▼14.0pp | +63.1pp |
† FY25 = fiscal 2025, through 2025-12-31; the trailing year is not available.A Withheld: our recalculation of this figure from its inputs did not match the reported value.B Withheld by our checks.
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-20 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Telix Pharmaceuticals' revenue last fiscal year?
Telix Pharmaceuticals reported revenue of $821.4M in fiscal 2025, up 55.4% from fiscal 2024.
What was Telix Pharmaceuticals' net income?
Telix Pharmaceuticals reported net income of −$15.5M in fiscal 2025, a net margin of −1.9%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

